Abstract
Background: Autologous hematopoietic stem cell transplantation (AHSCT) remains the treatment of choice in multiple myeloma (MM) patients (pts). The role of chemokine CXCR4 knows also as CXCR4 in hematopoietic stem cell homing engraftment, and in hematopoietic recovery after AHSCT is still not fully understood as well. Aims: In this prospective study we would like to investigate the influence CD184+ cells for overall survival (OS) and progression free survival (PFS) after AHSCT in MM pts. Methods: Forty eight pts with MM with median age 56 (range 21-76) were undergoing AHSCT in our center in years 2011-2013. Conditioning regimen was Melphalan. Number of all CD184+ cells were measured in harvested material. Results: All pts successfully engrafted. The median follow-up was over 8 years. Currently 21 pts (44%) are alive, including 8 pts (17%) in disease’s remission, and 13 are treated for MM progression. Twenty-seven pts died including 19 pts due to disease progression. The median OS was 7.8 years. In the study group a statistically significant correlation was found between OS, PFS and the number of CD184+ cells. In the context of OS and PFS, number of CD184+ cells was found to have a negative impact (correlation coefficient R = -0.32, p=0.0261, and correlation coefficient R = -0.41, p=0.0039 for OS and PFS retrospectively). As OS and PFS increased, the number of CD184+ cells decreased. Summary/Conclusion: The number of CD184+ cells could have a negative effect on both OS and PFS in multiple myeloma patients.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call